Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Launched by CITY OF HOPE MEDICAL CENTER · Dec 11, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the use of phytocannabinoids, which are natural compounds found in the cannabis plant, to help reduce symptoms of chronic peripheral neuropathy caused by chemotherapy in survivors of breast and colon cancer. Symptoms of this condition can include pain, tingling, numbness, and weakness in the limbs, and the trial will compare the effects of different types of phytocannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), to see which formulation works best for relief.

To be eligible for the study, participants must be at least 18 years old and have experienced neuropathy as a result of specific chemotherapy treatments. They should also be willing to use medical cannabis and participate in follow-up assessments. Participants can expect to be part of a supportive environment where their health and well-being are closely monitored throughout the trial. It’s important to note that individuals recently treated with chemotherapy or other neuropathic medications, as well as those with certain medical conditions, may not qualify for this study. If you or a loved one is interested in learning more about participating, it may be helpful to discuss this with your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Documented informed consent of the participant and/or legally authorized representative.
• • Assent, when appropriate, will be obtained per institutional guidelines
• • Agreement to allow the use of archival tissue from diagnostic tumor biopsies
• • If unavailable, exceptions may be granted with study principal investigator (PI) approval
• • Willingness to comply with all study interventions including the use of medical cannabis and follow-up assessments
• • Age: ≥ 18 years
• • Eastern Cooperative Oncology Group Performance Status Scale (ECOG) score ≤ 2
• • Ability to read and understand English for questionnaires
• • Patients must have either neuropathy ≥ 1 according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 scale or a neuropathy score of \> 3 on a 0-10 scale plus a FACT/GOG-Ntx score of \> 10
• • The patient's previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team
• • Total bilirubin ≤ 1.5 X upper limits of normal (ULN) (unless has Gilbert's disease) (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)
• • Aspartate aminotransferase (AST) ≤ 3 x ULN (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)
• • Alanine aminotransferase (ALT) ≤ 3 x ULN (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)
• • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)
• • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 months after the last dose of protocol therapy.
• • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
• Exclusion Criteria:
• • Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period. Note: Hormonal therapy is allowed
• • Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months
• • Concurrent use of other alternative medicines such as medical cannabis, herbal agents and high dose vitamins and minerals
• • Liver cirrhosis Child-Pugh B or C
• • Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry. (These patients may not be able to cooperate with this slightly invasive procedure or with the data collection process.)
• • History of diabetic neuropathy, neuropathy related to HIV, or other medical causes of chronic neuropathy in the baseline assessment including past medical history, any history of diabetes, alcoholism, and vitamin B deficiency
• • Previous medical cannabis use for any indication within 30 days of enrollment
• • Planned or actual changes in type of medications that could affect symptoms related to CIPN. New medications for the treatment of CIPN are not allowed during the study.
• • Subjects need to be on stable doses of CIPN medications for 4 weeks
• • Strong inhibitors or inducers of CYP3A4
• • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
• • Clinically significant uncontrolled illness
• • Diagnosis of Gilbert's disease
• • Females only: Pregnant or breastfeeding
• • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
• • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
• • Patients who have an allergy or an aversion to strawberry or strawberry flavoring